Innovation Theater Breakfast: From Acute Burns to Chronic Ulcers: The Expanding Role of Bromelain-Based Enzymatic Debridement (non-accredited/non-approved for CECH)

EscharEx® is a novel biological drug in late-stage clinical development for venous leg ulcers. It consists of a complex mixture of proteolytic enzymes enriched with bromelain, derived from the pineapple stem, enabling rapid and selective removal of non-viable tissue commonly present in hard-to-heal wounds. Emerging evidence also suggests biological effects beyond debridement, including promotion of granulation tissue, anti-inflammatory activity, and stimulation of cell migration. EscharEx is specifically formulated for chronic wounds and is based on the same active ingredient as NexoBrid®, an approved drug in the US, EU and Japan, for eschar removal in deep burns and widely adopted in burn centers worldwide.
This symposium will review the evolving mechanism of action of bromelain-based enzymatic therapy and its expansion from acute burn care to chronic wound management. Clinical data and case studies across acute injuries and hard-to-heal wounds will be presented, along with updates on the ongoing global VALUE Phase III trial in venous leg ulcers and planned studies in diabetic foot ulcers and pressure injuries.
Sponsored by MediWound.